GSE160204
ATAC-seq of lung cancer cell lines with doxycycline KRAS G12V and drug treatments
We modelled the effects of KRAS activation on three SCLC cell lines H2107, H82, H524 and investigated the effects of KRAS induction and various drug treatments on motif and chromatin accessibility profiles. Overall design: H2107-KRAS G12V and H524-KRAS G12V cells treated with doxycycline ± SCH772984 (1 µM) for 72 hours. H82-KRASG12V cells were treated with the following chemicals: doxycycline; doxycycline + SCH772984 (1 µM); doxycycline + SB747651A (5 µM); doxycycline + A-485 (400 nM); or doxycycline + SB747651A (5 µM) + A-485 (400 nM). After 72 hours treatment, these cells as well as corresponding non-treated control cells were collected and frozen.